AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1396108 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.4 mg or 0.8 mg/70 kg)
Number of subjects: 7
Study 1396108 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.4 mg or 0.8 mg/70 kg) + Naloxone (0.4 mg or 0.8 mg/70 kg)
Number of subjects: 7
Study 1396108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3888241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1 or 2.5 mg)
Number of subjects: 0
Study 3888241 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 0
Study 30864824 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupuncture stimulation (TEAS)
Number of subjects: 122
Study 30864824 — intervention group
Group type: COMPARATOR
Intervention: Mock transcutaneous electrical acupuncture stimulation (MTEAS)
Number of subjects: 122
Study 28214653 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT followed by CCRT (cisplatin 80 mg/m2 d1 and fluorouracil 800 mg/m2 civ d1‐5 for two cycles before CCRT)
Number of subjects: 476
Study 28214653 — intervention group
Group type: COMPARATOR
Intervention: CCRT alone (cisplatin 80 mg/m2 every 3 weeks concurrently with radiotherapy)
Number of subjects: 476
Study 28214653 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT followed by CCRT
Number of subjects: 476
Study 28214653 — intervention group
Group type: COMPARATOR
Intervention: CCRT alone
Number of subjects: 476
Study 25277597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine treatment for 2 years
Number of subjects: 46
Study 23179472 — intervention group
Group type: EXPERIMENTAL
Intervention: CicloMulsion(®)
Number of subjects: 52
Study 23179472 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune(®)
Number of subjects: 52
Study 21684425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic live attenuated influenza vaccine (PLAIV) against the influenza A (H1N1) virus
Number of subjects: 0
Study 21684425 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV)
Number of subjects: 0
Study 21684425 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N2 pandemic live attenuated influenza vaccine (PLAIV)
Number of subjects: 0
Study 21684425 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal live attenuated influenza vaccine (LAIV)
Number of subjects: 0
Study 18307373 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (10 mg IV infusion over 30 minutes or 60 mg orally) with fluvoxamine (100 mg orally once daily)
Number of subjects: 0
Study 18307373 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg orally twice daily)
Number of subjects: 0
Study 18307373 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (100 mg orally once daily)
Number of subjects: 0
Study 18307373 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (60 mg orally)
Number of subjects: 0
Study 17000242 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin therapy
Number of subjects: 120
Study 17000242 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin therapy (enoxaparin sodium)
Number of subjects: 120
Study 12708126 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% centbucridine hydrochloride
Number of subjects: 60
Study 12708126 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% centbucridine hydrochloride
Number of subjects: 60
Study 12708126 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lignocaine hydrochloride
Number of subjects: 60
Study 12708126 — intervention group
Group type: COMPARATOR
Intervention: Unanaesthetized control
Number of subjects: 60
Study 10509768 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast cereal (80 g for men, 60 g for women) consumed at breakfast for six weeks
Number of subjects: 224
Study 10509768 — intervention group
Group type: COMPARATOR
Intervention: Usual breakfast (control) for six weeks
Number of subjects: 224
Study 8948303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) and parenteral gold therapy (PGT)
Number of subjects: 40
Study 8948303 — intervention group
Group type: COMPARATOR
Intervention: Placebo and parenteral gold therapy (PGT)
Number of subjects: 40
Study 8948303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 40
Study 1746414 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 204
Study 1746414 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (placebo)
Number of subjects: 204
Study 7102441 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprivation condition (anticipated 4-hour food deprivation)
Number of subjects: 50
Study 7102441 — intervention group
Group type: EXPERIMENTAL
Intervention: High-restraint group
Number of subjects: 50
Study 7102441 — intervention group
Group type: COMPARATOR
Intervention: No deprivation condition
Number of subjects: 50
Study 7102441 — intervention group
Group type: COMPARATOR
Intervention: Low-restraint group
Number of subjects: 50
Study 30623309 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice (calcium silicate, sodium phosphate, 1450 ppm sodium monofluorophosphate)
Number of subjects: 256
Study 28452665 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-delivered cognitive-behavioral therapy (CBT) for depression
Number of subjects: 134
Study 28452665 — intervention group
Group type: COMPARATOR
Intervention: Minimal support control condition
Number of subjects: 134
Study 27061727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconstrained cervical arthroplasty
Number of subjects: 37
Study 24381276 — intervention group
Group type: EXPERIMENTAL
Intervention: IC training on an adaptive version of the stop-signal task (SST)
Number of subjects: 60
Study 24381276 — intervention group
Group type: COMPARATOR
Intervention: Active sham-training
Number of subjects: 60
Study 24381276 — intervention group
Group type: EXPERIMENTAL
Intervention: IC training
Number of subjects: 60
Study 21791142 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (1.7 g daily for 3 months)
Number of subjects: 206
Study 21791142 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 206
Study 19383589 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 degrees C hypothermia (group I)
Number of subjects: 55
Study 19383589 — intervention group
Group type: COMPARATOR
Intervention: 22 degrees C hypothermia (group II)
Number of subjects: 55
Study 17760732 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measurements for participants reporting increased abdominal girth
Number of subjects: 100
Study 17760732 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measurements for participants reporting sunken cheeks
Number of subjects: 100
Study 17760732 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measurements for participants reporting reduced diameter of the legs
Number of subjects: 100
Study 17760732 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measurements for participants reporting increased neck girth
Number of subjects: 100
Study 15886433 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom data acquisition system (DA) - data collected every minute
Number of subjects: 16
Study 15886433 — intervention group
Group type: COMPARATOR
Intervention: Medical record (MR) - data collected hourly
Number of subjects: 16
Study 12492626 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid (10% of energy) with varying levels of linoleic acid
Number of subjects: 0
Study 12492626 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids
Number of subjects: 0
Study 10321136 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9800145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylnaltrexone 19.2 mg/kg
Number of subjects: 0
Study 9800145 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 0.05 mg/kg
Number of subjects: 0
Study 1863121 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency positive pressure ventilation (HFPPV)
Number of subjects: 346
Study 1863121 — intervention group
Group type: COMPARATOR
Intervention: Low frequency positive pressure ventilation (LFPPV)
Number of subjects: 346
Study 1863121 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency positive pressure ventilation (HFPPV) in infants with hyaline membrane disease
Number of subjects: 346
Study 1863121 — intervention group
Group type: COMPARATOR
Intervention: Low frequency positive pressure ventilation (LFPPV) in infants with hyaline membrane disease
Number of subjects: 346
Study 6193350 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg MDL‐899
Number of subjects: 8
Study 6193350 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg MDL‐899 with 100 mg atenolol
Number of subjects: 8
Study 6193350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31172750 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized control pulses for quantum sensing
Number of subjects: 0
Study 31172750 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized pulse sequences
Number of subjects: 0
Study 29653344 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized comprehensive early intervention care (EIP)
Number of subjects: 77
Study 29653344 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 77
Study 26158873 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelial gap geometry
Number of subjects: 0
Study 26158873 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical coupling between actomyosin cable contraction and cell crawling
Number of subjects: 0
Study 26158873 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational modelling
Number of subjects: 0
Study 23688137 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor enrichment group (daily olfactory/tactile stimulation and paired sensory exercises)
Number of subjects: 0
Study 23688137 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23688137 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor enrichment group
Number of subjects: 0
Study 23688137 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched group
Number of subjects: 0
Study 21833000 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2232
Study 21833000 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 2232
Study 18246334 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Alzheimer's disease (AD)
Number of subjects: 38
Study 18246334 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 38
Study 16946455 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured treatment interruption (STI) of antiretroviral therapy
Number of subjects: 0
Study 16946455 — intervention group
Group type: COMPARATOR
Intervention: Continuous antiretroviral therapy
Number of subjects: 0
Study 12723462 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone with low-dose ritonavir (200 mg each, four doses)
Number of subjects: 10
Study 12723462 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone with low-dose ritonavir
Number of subjects: 10
Study 12723462 — intervention group
Group type: COMPARATOR
Intervention: Trazodone plus placebo
Number of subjects: 10
Study 10677399 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 38
Study 10677399 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 38
Study 8788541 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (vodka and tonic to achieve a blood alcohol level of 0.08%)
Number of subjects: 20
Study 8788541 — intervention group
Group type: COMPARATOR
Intervention: Nonalcohol beverage (tonic only)
Number of subjects: 20
Study 8788541 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 20
Study 1299797 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam
Number of subjects: 0
Study 1299797 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 0
Study 6490928 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical interventions
Number of subjects: 12
Study 30371800 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + goserelin
Number of subjects: 218
Study 30371800 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 218
Study 29862258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-trampoline physical activity (20 min after school, 5 days/week for 10 weeks)
Number of subjects: 57
Study 29862258 — intervention group
Group type: COMPARATOR
Intervention: Control group (same classes and care service, no extra trampoline training)
Number of subjects: 57
Study 26690356 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (0.1 mg/kg)
Number of subjects: 28
Study 26690356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (100 µg/kg)
Number of subjects: 28
Study 26690356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 24293176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT)
Number of subjects: 177
Study 22836812 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed intervention materials (patient osteoporosis brochure and a letter explaining how to self-schedule a DXA scan)
Number of subjects: 2997
Study 22836812 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2997
Study 20217128 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ selected peripheral blood progenitor cells (PBPC) from related allogeneic donors (group A)
Number of subjects: 50
Study 20217128 — intervention group
Group type: COMPARATOR
Intervention: Unselected peripheral blood progenitor cells (PBPC) from related allogeneic donors (group B)
Number of subjects: 50
Study 17351370 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg twice daily for 4 weeks
Number of subjects: 13
Study 17351370 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg twice daily for 4 weeks
Number of subjects: 13
Study 16318148 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion plus Chinese medicine
Number of subjects: 79
Study 16318148 — intervention group
Group type: COMPARATOR
Intervention: Simple Chinese medicine
Number of subjects: 79
Study 12077689 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting (EVH)
Number of subjects: 140
Study 12077689 — intervention group
Group type: COMPARATOR
Intervention: Traditional open vein harvesting (OVH)
Number of subjects: 140
Study 9706951 — intervention group
Group type: EXPERIMENTAL
Intervention: RS‐25259 30 microg/kg
Number of subjects: 218
Study 9706951 — intervention group
Group type: EXPERIMENTAL
Intervention: RS‐25259 0.3-30 microg/kg
Number of subjects: 218
Study 9706951 — intervention group
Group type: COMPARATOR
Intervention: RS‐25259
Number of subjects: 218
Study 9773700 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oxycodone and 10 mL 0.5% bupivacaine (group OB)
Number of subjects: 45
Study 9773700 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene plexus block (group IPB)
Number of subjects: 45
Study 9773700 — intervention group
Group type: COMPARATOR
Intervention: 10 mL 0.5% bupivacaine (group B)
Number of subjects: 45
Study 9773700 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study 2496213 — intervention group
Group type: COMPARATOR
Intervention: Low-dose calcium and phosphorus (5 mM each; 20 mg/dl of Ca and 15.5 mg/dl of P)
Number of subjects: 25
Study 2496213 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose calcium and phosphorus (15 mM each; 60 mg/dl of Ca and 46.5 mg/dl of P)
Number of subjects: 25
Study 2496213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (low and high-dose)
Number of subjects: 25
Study 1006147 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 6
Study 1006147 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise in supine position
Number of subjects: 6
Study 1006147 — intervention group
Group type: COMPARATOR
Intervention: Resting supine position
Number of subjects: 6
Study 31203062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Reality (MR) based planning (Group B)
Number of subjects: 60
Study 31203062 — intervention group
Group type: COMPARATOR
Intervention: 2-dimensional standard planning route (Group A)
Number of subjects: 60
Study 28830511 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture (WAA)
Number of subjects: 60
Study 28830511 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study 25654750 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential training in outer and middle ear screening
Number of subjects: 36
Study 23808950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Block (CB) method
Number of subjects: 137
Study 23808950 — intervention group
Group type: COMPARATOR
Intervention: Smear cytology
Number of subjects: 137
Study 23808950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Block (CB) method for bile duct cancer
Number of subjects: 137
Study 23808950 — intervention group
Group type: COMPARATOR
Intervention: Smear cytology for bile duct cancer
Number of subjects: 137
Study 23808950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Block (CB) method for pancreatic head cancer
Number of subjects: 137
Study 23808950 — intervention group
Group type: COMPARATOR
Intervention: Smear cytology for pancreatic head cancer
Number of subjects: 137
Study 23808950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Block (CB) method for gallbladder cancer
Number of subjects: 137
Study 23808950 — intervention group
Group type: COMPARATOR
Intervention: Smear cytology for gallbladder cancer
Number of subjects: 137
Study 21666556 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone administered in 100 mL of physiologic saline given intravenously 20 minutes before anesthesia induction
Number of subjects: 70
Study 21666556 — intervention group
Group type: COMPARATOR
Intervention: 2 mL NaCl 0.9% in 100 mL of physiologic saline (control group)
Number of subjects: 70
Study 19417877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (50 mg)
Number of subjects: 51
Study 19417877 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium (25 mg)
Number of subjects: 51
Study 16394842 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic nevirapine
Number of subjects: 15
Study 16394842 — intervention group
Group type: COMPARATOR
Intervention: Brand name nevirapine
Number of subjects: 15
Study 16394842 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic lamivudine
Number of subjects: 15
Study 16394842 — intervention group
Group type: COMPARATOR
Intervention: Brand name lamivudine
Number of subjects: 15
Study 16394842 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic zidovudine
Number of subjects: 15
Study 16394842 — intervention group
Group type: COMPARATOR
Intervention: Brand name zidovudine
Number of subjects: 15
Study 14968598 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with background infusion (3 ml PCEA, lock out 30 min, continuous infusion 5 ml/hr)
Number of subjects: 90
Study 14968598 — intervention group
Group type: COMPARATOR
Intervention: Infuser group (continuous infusion 5 ml/hr)
Number of subjects: 90
Study 14968598 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with background infusion
Number of subjects: 90
Study 14968598 — intervention group
Group type: COMPARATOR
Intervention: Infuser group
Number of subjects: 90
Study 14968598 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA group
Number of subjects: 90
Study 11816957 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% sodium tetradecyl sulphate
Number of subjects: 100
Study 11816957 — intervention group
Group type: COMPARATOR
Intervention: 3% polidocanol
Number of subjects: 100
Study 9160657 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha2b 3 million U three times weekly for 12 months
Number of subjects: 107
Study 9160657 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 107
Study 7695058 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 120 mg once a day
Number of subjects: 39
Study 7695058 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study 3302705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cop 1 (20 mg daily for two years)
Number of subjects: 50
Study 3302705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline alone daily for two years)
Number of subjects: 50
Study 3302705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cop 1 (20 mg daily for two years) among less disabled patients (Kurtzke score 0 to 2)
Number of subjects: 50
Study 3302705 — intervention group
Group type: COMPARATOR
Intervention: Placebo among less disabled patients (Kurtzke score 0 to 2)
Number of subjects: 50
Study 3302705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cop 1 (20 mg daily for two years) among more disabled patients (Kurtzke score 3 to 6)
Number of subjects: 50
Study 3302705 — intervention group
Group type: COMPARATOR
Intervention: Placebo among more disabled patients (Kurtzke score 3 to 6)
Number of subjects: 50
Study 3302705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cop 1 (20 mg daily for two years) among less disabled patients
Number of subjects: 50
Study 3302705 — intervention group
Group type: COMPARATOR
Intervention: Placebo among less disabled patients
Number of subjects: 50
Study 3302705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cop 1 (20 mg daily for two years) among more disabled patients
Number of subjects: 50
Study 3302705 — intervention group
Group type: COMPARATOR
Intervention: Placebo among more disabled patients
Number of subjects: 50
Study 30111298 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) interventions, mean of 2.5 MI interventions per week per patient
Number of subjects: 83
Study 30111298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program including training of staff in MI and improvements of facilities for physical exercise
Number of subjects: 83
Study 27550085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention group (CIG; n = 66)
Number of subjects: 96
Study 27550085 — intervention group
Group type: COMPARATOR
Intervention: Care as usual group (CAUG; n = 30)
Number of subjects: 96
Study 23892777 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg/day for first 3 days, then 1 mg/day for 4 days)
Number of subjects: 34